Journal
CLEARANCE OF DYING CELLS IN HEALTHY AND DISEASED IMMUNE SYSTEMS
Volume 1209, Issue -, Pages 99-108Publisher
WILEY-BLACKWELL
DOI: 10.1111/j.1749-6632.2010.05763.x
Keywords
cancer; immunogenic cell death; immunotherapy; chemotherapy; toll-like receptor
Categories
Ask authors/readers for more resources
The concept of immunogenic chemotherapy that has recently emerged relies upon the capacity of a cytotoxic compound to trigger a cell-death modality. This modality elicits cross-priming by dendritic cells of tumor antigen-specific T cells that will contribute to the tumoricidal activity of the compound and protect the host against relapse. In contrast, most anticancer drugs elicit nonimmunogenic apoptosis that is not accompanied with an immunizing property. This review will discuss some molecular and metabolic changes required at the level of the tumor that must engage key pathways at the level of the host for the induction of Tc1 polarized protective T cell responses during chemotherapy. We will summarize the immune adjuvants that can boost the immunogenicity of cell death to augment the efficacy of chemotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available